Generic drug
Everolimus price, strengths & recalls
Pharmacies pay $789.73 for 30 tablets of Everolimus 10 mg tablet this week, and from $50.66 to $789.73 across its 6 priced strengths and forms. 8 manufacturers make it. It is in shortage (being discontinued). 5 recalls are ongoing. Its official label last changed on July 8, 2026.
Being discontinued5 open recallsGeneric- Fair cash price
- $918.69
- Strengths
- 6
- Makers
- 8
- Updated
- Nov 11
Everolimus price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.25 mg tablet | $1.69 | $50.66 / 30 tablets |
| 0.5 mg tablet | $3.20 | $96.07 / 30 tablets |
| 0.75 mg tablet | $3.87 | $116.19 / 30 tablets |
| 1 mg tablet | $5.49 | $164.57 / 30 tablets |
| 5 mg tablet | $14.77 | $443.12 / 30 tablets |
| 10 mg tablet | $26.32 | $789.73 / 30 tablets |
The lowest cost per tablet is 0.25 mg tablet at $1.69. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Brand names of everolimus
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Shortages
- Everolimus, Tablet, .5 mg (NDC 49884-159-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, 1 mg (NDC 49884-283-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, .25 mg (NDC 49884-158-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, .75 mg (NDC 49884-160-02)A business decision was made to withdraw from sale.
- Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 10 mg (NDC 0093-7769-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 5 mg (NDC 0093-7767-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 10 mg (NDC 49884-128-91)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 5 mg (NDC 49884-125-91)Discontinuation of the manufacture of the drug
- Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Everolimus
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2010
WARNING: MALIGNANCIES and SERIOUS INFECTIONS; KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY; and MORTALITY IN HEART TRANSPLANTATION
WARNING: MALIGNANCIES and SERIOUS INFECTIONS; KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY; and MORTALITY IN HEART TRANSPLANTATION
See full prescribing information for complete boxed warning.
Only physicians experienced in immunosuppressive therapy and management of transplant patients should use everolimus (5.1)
Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression (5.2, 5.3)
Increased incidence of kidney graft thrombosis (5.4)
Reduced doses of cyclosporine are required for use in combination with everolimus in order to reduce nephrotoxicity (2.4, 2.5, 5.6, 12.7, 12.8)
Increased mortality in a heart transplant clinical trial. Use in heart transplantation is not recommended (5.7)
Malignancies and Serious Infections
Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe everolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient [see Warnings and Precautions (5.1)].
Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression [see Warnings and Precautions (5.2, 5.3)].
Kidney Graft Thrombosis
An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days posttransplantation [see Warnings and Precautions (5.4)].
Nephrotoxicity
Increased nephrotoxicity can occur with use of standard doses of cyclosporine in combination with everolimus. Therefore, reduced doses of cyclosporine should be used in combination with everolimus in order to reduce renal dysfunction. It is important to monitor the cyclosporine and everolimus whole blood trough concentrations [see Dosage and Administration (2.4, 2.5), Warnings and Precautions (5.6), Clinical Pharmacology (12.7, 12.8)].
Mortality in Heart Transplantation
Increased mortality, often associated with serious infections, within the first three months post transplantation was observed in a clinical trial of de novo heart transplant patients receiving immunosuppressive regimens with or without induction therapy. Use in heart transplantation is not recommended [see Warnings and Precautions (5.7)].
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 10 approved generic applications on the market
Everolimus questions
How much does everolimus cost without insurance?
Pharmacies pay about $789.73 for 30 tablets of everolimus 10 mg tablet ($26.32 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $918.69. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of everolimus?
Is everolimus in shortage?
Yes. 12 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has everolimus been recalled?
6 recalls on record, 5 ongoing. Recalls name specific lots - check yours.
When did the everolimus label last change?
The official label was last updated on July 8, 2026 (version 9). See what changed.
Talk about everolimus
No comments yet. Questions, tips, what worked for you - start the conversation.